Meta Pixel

Ferronova Series A

Australia|Life Sciences

Overview

Surgery remains the only curative treatment for most solid tumour cancer patients, with around 80% of all new cancer patients globally expected to undergo surgery. Yet, despite successful operations, many experience devastating cancer recurrence, often due to microscopic disease left behind.

Ferronova’s mission is to improve surgical precision and patient outcomes so that cancer doesn’t return.

Investment Highlight:

  • Initial focus: Stomach and esophageal cancers - three-year post-surgery survival as low as 27%.
  • Disease burden: The third and sixth leading causes of cancer deaths globally, with 1.8 million new cases each year.
  • Technology: A unique combination of injectable magnetic nanoparticles (FerroTrace®), a companion surgical probe (FerroMag®), and artificial intelligence (AI) to help surgeons identify and remove all cancerous tissue.
  • Clinical validation: 84 patients treated in clinical trials to date across multiple studies.
  • Leadership: Experienced medtech executives with previous company exits to global strategics.
  • Global reach: Clinical collaborations with leading hospitals across the US, Europe and Australia.
  • Strategic investor: Ultragreen.AI (Renew Pharmaceuticals) - providing both capital and global distribution capabilities.
  • Strong backing: Supported by top-tier investors including Uniseed/UniSuper, Artesian Venture Partners, and Ultragreen.ai.

Problem and Solution

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.



Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.

Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.


Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mollis, eget aliquet odio tincidunt.
Phasellus faucibus sem mauris, sed iaculis nisl egestas sed.
Sed sit amet gravida elit, sagittis sollicitudin nulla. Vivamus auctor arcu eu scelerisque convallis. Phasellus scelerisque ultrices tincidunt. Curabitur odio libero, faucibus et felis nec, pulvinar facilisis urna. Interdum et malesuada fames ac ante ipsum primis in faucibus. Maecenas ultrices in velit at ultrices.


Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet. Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim.

In dui nisl, vestibulum eu

Market Opportunity

Cras eleifend purus vitae mattis imperdiet.



Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.



Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.



Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis

Competitive Advantage

Cras eleifend purus vitae mattis imperdiet.



Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.



Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.



Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus e

Highlights & Milestones

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.



Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.

Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.


Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mollis, eget aliquet odio tincidunt.
Phasellus faucibus sem mauris, sed iaculis nisl egestas sed.
Sed sit amet gravida elit, sagittis sollicitud

See more exiting opportunities on CapitalHQ

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

ProxyTwin

ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...

flag_australia
Australia AUD
Artificial Intelligence Seed Round

HorizonTwo Capital Partners

HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.

flag_australia
Australia AUD
Advanced Manufacturing Private Placement

The Insides Company

First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.

flag_new zealand
New Zealand AUD
Medical Devices Series A

DCARB

We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.

flag_australia
Australia CAD
Green Hydrogen Series B+

Grabba Technologies Pty Ltd

Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.

flag_australia
Australia AUD
Electronic Equipment & Instruments Private Placement

Join over 45,000+ sophisticated investors

Join Now